Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026, along with the Limited Review Report for the said period.

Corporate Office: Solara Active Pharma Sciences Limited TICEL Bio Park, 6th Floor, ~ ' SOLARA Module No. 601, 602, 603, Phase II – CSIR Road, , ,., Active Pharma Sciences Taramani, Chennai, Tamil Nadu – 600113. Tel: +91 44 4344 6700 Fax: +91 44 47406190 E-mail: investors@solara.co.in Website: www.solara.co.in Date: October 16, 2026 The BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G, Bandra-Kurla Dalal Street, Mumbai – 400 001 Complex, Bandra (E), Mumbai – 400 051 Scrip Code: 541540, 890202 Symbol: SOLARA, SOLARAPP1 Dear Sir/Madam, Sub: Outcome of Board Meeting - Unaudited Financial Results for the quarter and half year ended September 30, 2026. Ref: Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform you that the Board of Directors of the Company at their meeting held today i.e. Friday, October 16, 2026, have considered and approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026, together with the Limited Review Report issued by M/s. Deloitte Haskins & Sells, Chartered Accounts, Statutory Auditor of the Company. Pursuant to Regulation 33 of the Listing Regulations, we enclose herewith a copy of the Unaudited Financial Results (Standalone and Consolidated) along with the Limited Review Report. Please note that the aforesaid unaudited Financial Results will also be available on the Company's website at https://solara.co.in/investor-relations/financial-information. The Board Meeting commenced at 12:30 P.M and concluded at 01:20 P.M. This is for your kind information and records. Thanking you, Yours faithfully, For Solara Active Pharma Sciences Limited Pooja Jaya Kumar Company Secretary & Compliance Officer ICSI Membership No.: A57415 Encl.: As above Solara Active Pharma Sciences Limited - CIN: L24230MH2017PLC291636 Registered Office: ‘Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703 / Tel: +91-22- 2087 0033 Chartered Accountants Prestige Trade Tower, Level 19 Deloitte 46. Palace Road, High Grounds Bengaluru - 560 001 Haskins & Sells LLP Karnataka, India Tel: +91 80 6188 6000 Fax: +91 80 6188 6011 INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF SOLARA ACTIVE PHARMA SCIENCES LIMITED 1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of SO LARA ACTIVE PHARMA SCIENCES LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and six months ended September 30, 2026 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the LODR Regulations"). 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the LODR Regulations, to the extent applicable. 4. The Statement includes the results of the following entities: SI. No. Name of the entities 1 Solara Active Pharma Sciences Limited, the Parent 2 Shasun USA Inc., wholly owned subsidiary 3 Synthix Global Pharma Solutions Limited, wholly owned subsidiary 4 Chemsynth Laboratories Private Limited, subsidiary 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the LODR Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. Regd. Office: One International Centre, Tower 3, 31" Floor, Senapati Ba pat Marg, Elphinstone Road (West). Mumbai • 400 013, Maharashtra, India (LLP Identification No. AAB-8737) Deloitte Haskins & Sel s LLP 6. The consolidated unaudited financial results include the interim financial information of 2 subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total assets of Rs. 6.75 Crores as at September 30, 2026, total revenue of Rs. Nil and Rs. Nil for the quarter and six months ended September 30, 2026 respectively, total net loss after tax of Rs. 0.02 Crores and Rs. 0.03 Crores For the quarter and six months ended September 30, 2026 respectively and other comprehensive loss of Rs. Nil and Rs. Nil for the quarter and six months ended September 30, 2026 respectively and net cash inflows of Rs. 0.01 crores for the six months ended September 30, 2026 as considered in the Statement. In our opinion and according to the information and explanations given to us by the Board of Directors, these financial information are not material to the Group. Our Conclusion on the Statement is not modified in respect of our reliance on the interim Financial information certified by the Management. For DELOITTE HASKINS & SELLS LLP Chartered Accountants (Firm's Registration No. 117366W/W- 00018) :1:.l:::t.Ck Sandeep (Partner) (Membership No. 220411) (UDIN: 26220411KSATWI8970) Place: Bengaluru Date: October 16, 2026 Page 2 of2 ~... 6- S ,,_ .O .... ,L ...A .. ,,R . ·A ·•··· SOLARA A CC /NT : IV l2E 42 P 30H MA HR 2M 01A 7P S LC C2IE 9N 16C 3E 6S LIMITED Regd. Office: 9th Floor, 'Cyber One', Unil No. 902. Plot No. 4 & 6, Sector 30A, Vashi, Navf Mumbai -400 703 Corporate Offfce: TICEL BIO PARK, 6th floor Module No. 601,602,603. Phase II -CS\R Road. Taramani, Chennai, Tamil Nadu -600113 STATEMENT Of UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30. 2026 {Rs. In Crores except per shore data) Year to dote Year to date Corresponding 3 SI. 3 months ended Preceding months ended In llgures for the figures for lhe Previous Financial Particulars 3 months ended current period previous period Year ended No. the previous year ended ended 30.09.2026 JD.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 UNAUDITED UNAUDITED UNAUDITED UNAUDITED UNAUDITED AUDITED I Revenue from operations 417 34 381.60 313.54 798.94 632.69 1.36 [Showing first 8,000 characters — download PDF for full document]